Worldwide Study Finder

Not applicableCompletedINTERVENTIONAL

Evolutive Potential of Embryos Obtained From Oocytes After Luteal Phase Ovarian Stimulation

ClinicalTrials.gov · NCT01645241 · Registry updated: 2014-10-27

Condition / research focus: INFERTILITY; Fertility Preservation; Ovulation Induction; Vitrification; Oocyte Donation
Sponsor: Fundacion Dexeus
Countries with listed sites: Spain
Registry dates and results: Start: 2012-07. Completion: 2013-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

gonadotropins plus GnRH antagonists (drug) — also listed as: Ovarian stimulation
ganirelix (drug) — also listed as: the investigators will administer in the 13th-15th cycle day simultaneously 0.25 mg/day of ganirelix

Where the study takes place — 1 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Early Phase 1CompletedINTERVENTIONAL

Response of VEGF and AT-II to HCG in PCOS

ClinicalTrials.gov · NCT02265861 · Registry updated: 2014-10-16

Condition / research focus: Polycystic Ovary Syndrome
Sponsor: Nanjing University School of Medicine
Countries with listed sites: No country reported
Registry dates and results: Start: 2010-01. Completion: 2012-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

HCG (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Hormonal Stimulation in IUI Treatment: Is Clomifen Combined With Ethinyl Estradiol Better, Worse or Equal to Menopur

ClinicalTrials.gov · NCT01569945 · Registry updated: 2014-09-10

Condition / research focus: Subfertility
Sponsor: University Hospital, Gasthuisberg
Countries with listed sites: Belgium
Registry dates and results: Start: 2004-09. Completion: 2011-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Clomifen, Ethinyl Estradiol (drug)
Menotropins (drug)

Where the study takes place — 1 listed sites

Leuven University Fertility Center
Leuven, Vlaams Brabant, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Simplified Medical Abortion in Rural India

ClinicalTrials.gov · NCT01827995 · Registry updated: 2014-08-15

Condition / research focus: Pregnancy
Sponsor: Karolinska Institutet
Countries with listed sites: India
Registry dates and results: Start: 2013-04. Completion: 2014-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Self assessment (other) — also listed as: Duo test
Routine assessment (other)

Where the study takes place — 1 listed sites

ARTH
Udaipur, Rajasthan, India
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Corifollitropin Alfa Application in PCOS Patients

ClinicalTrials.gov · NCT02215135 · Registry updated: 2014-08-13

Condition / research focus: In Vitro Fertilization
Sponsor: Shin Kong Wu Ho-Su Memorial Hospital
Countries with listed sites: Taiwan
Registry dates and results: Start: 2014-01. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Corifollitropin alfa (drug) — also listed as: elonva

Where the study takes place — 1 listed sites

Department of Obstetrics and Gynecology, Shin-Kong Wu Ho-Su Memorial Hospital
Taipei, Taiwan
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

GONAL-f CONSORT (Consistency in r-hFSH Starting Doses for Individualised Treatment)

ClinicalTrials.gov · NCT01100333 · Registry updated: 2014-07-31

Condition / research focus: Infertility
Sponsor: Merck KGaA, Darmstadt, Germany
Countries with listed sites: Germany
Registry dates and results: Start: 2008-04. Completion: 2011-07 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Recombinant human follicle stimulating hormone (r-hFSH) (drug) — also listed as: Gonal-f

Where the study takes place — 1 listed sites

Universitätsmedizin Charitè Berlin, Schumann Straße 20/21
Berlin, State of Berlin, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Study Using Recombinant Human Chorionic Gonadotrophin (rhCG, Ovidrel®) in the Induction of Final Follicle Maturation and Early Luteinization in Chinese Women Undergoing in Vitro Fertilization and Embryo Transfer (IVF/ET)

ClinicalTrials.gov · NCT01081756 · Registry updated: 2014-07-31

Condition / research focus: Infertility
Sponsor: Merck KGaA, Darmstadt, Germany
Countries with listed sites: China
Registry dates and results: Start: 2003-12. Completion: 2004-09 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

r-hCG (drug) — also listed as: Ovitrelle or Ovidrel
Urinary-hCG (drug) — also listed as: Profasi

Where the study takes place — 1 listed sites

Peking University 3rd Hopistal
Beijing, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Clomiphene Citrate Plus Gonadotropins and GnRH Antagonist Versus Flexible GnRH Antagonist Protocol Versus Microdose GnRH Agonist Protocol in Poor Responders Undergoing IVF

ClinicalTrials.gov · NCT02201914 · Registry updated: 2014-07-28

Condition / research focus: Poor Responders; IVF; Clomiphene Citrate; GnRH Agonist; GnRH Antagonist
Sponsor: Bioroma
Countries with listed sites: Italy
Registry dates and results: Start: 2014-01. Completion: 2014-11 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Clomiphene citrate (drug)
Daily FSH and LH plus Cetrorelix (drug)
Triptorelin plus daily FSH anh LH (drug)

Where the study takes place — 1 listed sites

Bioroma
Rome, Rome, Italy
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2 / Phase 3TerminatedINTERVENTIONAL

Growth Hormone in Poor Responders to IVF Trial

ClinicalTrials.gov · NCT01616225 · Registry updated: 2014-07-23

Condition / research focus: Infertility
Sponsor: Pacific Centre for Reproductive Medicine
Countries with listed sites: Canada
Registry dates and results: Start: 2012-06. Completion: 2015-08 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Saizen (Human Growth Hormone) (drug)
Saizen (Human Growth Hormone) (drug)
No Saizen Control (Standard IVF Protocol) (drug)

Where the study takes place — 1 listed sites

Pacific Centre for Reproductive Medicine
Burnaby, British Columbia, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

A Study to Evaluate the Ease of Use, Local Tolerance, Safety and Effectiveness of Gonal-f® (Filled-by-mass in a Prefilled Pen)

ClinicalTrials.gov · NCT01115725 · Registry updated: 2014-07-17

Condition / research focus: Infertility
Sponsor: Merck KGaA, Darmstadt, Germany
Countries with listed sites: Greece
Registry dates and results: Start: 2005-11. Completion: 2008-07 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Gonal-f® (follitropin alfa) (drug) — also listed as: Recombinant human follicle stimulating hormone (r-hFSH)

Where the study takes place — 1 listed sites

EMBRYOGENESIS IVF Unit
Athens, Kifisias aV, Greece
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

A Prospective, Multi-centric Observational Study to Determine the Mono-bifollicular Development in Infertile Women Subjected to Ovulation Induction With Follitropin α

ClinicalTrials.gov · NCT01111084 · Registry updated: 2014-07-16

Condition / research focus: Ovulation Induction
Sponsor: Merck KGaA, Darmstadt, Germany
Countries with listed sites: Spain
Registry dates and results: Start: 2004-03. Completion: 2005-06 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Follitropin alpha (r-FSH) (drug) — also listed as: Gonal-f

Where the study takes place — 1 listed sites

Hospital Ntra. Sra. De Valme
Seville, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Non-invasive Chromosomal Examination of Trisomy Study

ClinicalTrials.gov · NCT01511458 · Registry updated: 2014-07-14

Condition / research focus: Trisomy 21
Sponsor: Roche Sequencing Solutions
Countries with listed sites: Belgium · Canada · Italy · Netherlands · Sweden · United States
Registry dates and results: Start: 2012-03. Completion: 2014-05 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 36 listed sites

Tucson Medical Center
Tucson, Arizona, United States
Site recruitment: Not reported
East Bay Perinatal Associates
Oakland, California, United States
Site recruitment: Not reported
Stanford University
Palo Alto, California, United States
Site recruitment: Not reported
Perinatal Diagnostic Center
Riverside, California, United States
Site recruitment: Not reported
University of California San Diego
San Diego, California, United States
Site recruitment: Not reported
California Pacific Medical Center
San Francisco, California, United States
Site recruitment: Not reported
University of California San Francisco
San Francisco, California, United States
Site recruitment: Not reported
The Institute of Prenatal Diagnosis and Reproductive Medicine
San Gabriel, California, United States
Site recruitment: Not reported
Christiana Care Health System
Newark, Delaware, United States
Site recruitment: Not reported
Altus Research
Lake Worth, Florida, United States
Site recruitment: Not reported
Fetal Diagnostic Institute of the Pacific
Honolulu, Hawaii, United States
Site recruitment: Not reported
Northshore University Health System
Evanston, Illinois, United States
Site recruitment: Not reported
Norton Healthcare
Louisville, Kentucky, United States
Site recruitment: Not reported
Brigham and Women's Hospital - Center for Fetal Medicine and Prenatal Genetics
Boston, Massachusetts, United States
Site recruitment: Not reported
Minnesota Perinatal Associates
Minneapolis, Minnesota, United States
Site recruitment: Not reported
Robert Wood Johnson School of Medicine
New Brunswick, New Jersey, United States
Site recruitment: Not reported
St. Peters University Medical Center
New Brunswick, New Jersey, United States
Site recruitment: Not reported
Columbia University
New York, New York, United States
Site recruitment: Not reported
Duke University Medical Center
Durham, North Carolina, United States
Site recruitment: Not reported
Northwest Perinatal Center
Portland, Oregon, United States
Site recruitment: Not reported
Oregon Health Sciences University
Portland, Oregon, United States
Site recruitment: Not reported
Abington Memorial Hospital
Abington, Pennsylvania, United States
Site recruitment: Not reported
Thomas Jefferson Univeristy Hospital
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported
Women's Health Care Group of Pennsylvania
Wynnewood, Pennsylvania, United States
Site recruitment: Not reported
Partners in Obstetrics and Gynecology
Pawtucket, Rhode Island, United States
Site recruitment: Not reported
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Site recruitment: Not reported
University Hospitals Leuven
Leuven, Belgium
Site recruitment: Not reported
Early Risk Assessment Program - University of Alberta
Calgary, Alberta, Canada
Site recruitment: Not reported
Ottawa Hospital and Research Institute
Ottawa, Ontario, Canada
Site recruitment: Not reported
Mount Sinai University
Toronto, Ontario, Canada
Site recruitment: Not reported
University of Toronto
Toronto, Ontario, Canada
Site recruitment: Not reported
University of Perugia
Perugia, Italy
Site recruitment: Not reported
Leiden University Medical Center
Leiden, Netherlands
Site recruitment: Not reported
Maastricht University Medical Center
Maastricht, Netherlands
Site recruitment: Not reported
Sahlgrenska University Medical Center
Gothenburg, Sweden
Site recruitment: Not reported
Karolinska University Hospital
Stockholm, Sweden
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableTerminatedOBSERVATIONAL

An Observational Study to Compare the Dose of Gonal-fTM FbM Prescribed by the Doctor With the Recommendation of the Dose Calculator Consort and to Evaluate the Ease of Use of Pre-filled Pen of Gonal-fTM FbM Pen

ClinicalTrials.gov · NCT01080729 · Registry updated: 2014-07-02

Condition / research focus: Multifollicular Stimulation
Sponsor: Merck KGaA, Darmstadt, Germany
Countries with listed sites: Belgium
Registry dates and results: Start: 2009-02. Completion: 2010-02 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Recombinant-follicle stimulating hormone (r-FSH) (drug) — also listed as: GONAL-f™

Where the study takes place — 1 listed sites

ZNA Middelheim
Antwerp, Lindendreef 1, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

The Role of a Semi-Quantitative Urine Pregnancy Test and Pregnancy Questionnaire After Uterine Evacuation for Undesired Pregnancy of Uncertain Location

ClinicalTrials.gov · NCT01596972 · Registry updated: 2014-07-01

Condition / research focus: Follow-up After Uterine Evacuation
Sponsor: Planned Parenthood League of Massachusetts
Countries with listed sites: United States
Registry dates and results: Start: 2012-06. Completion: 2013-05 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

dBest semi-quantitative urine pregnancy test (device)

Where the study takes place — 1 listed sites

Planned Parenthood League of Massachusetts
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Effect of GnRH Antagonist vs Agonist Long on IVF Outcome, Peak Estradiol Level,and Duration of Stimulation

ClinicalTrials.gov · NCT01669291 · Registry updated: 2014-06-04

Condition / research focus: Fertility
Sponsor: Main Line Fertility Center
Countries with listed sites: United States
Registry dates and results: Start: 2012-07. Completion: 2014-05 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Bravelle and Menopur (drug)
Agonist (drug) — also listed as: Leuprolide Acetate, Lupron
Antagonist (drug) — also listed as: ganirelix acetate, cetrorelix acetate

Where the study takes place — 1 listed sites

Main Line Fertility Center
Bryn Mawr, Pennsylvania, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath

ClinicalTrials.gov · NCT00580034 · Registry updated: 2014-06-03

Condition / research focus: Lymphoma; Myeloma; Leukemia; Myelodysplasia; Solid Tumors
Sponsor: David Rizzieri, MD
Countries with listed sites: United States
Registry dates and results: Start: 2003-02. Completion: 2013-04 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Campath Purged Non-myeloablative ASCT (drug)
Donor Apheresis (procedure)

Where the study takes place — 1 listed sites

Duke University Health Systems
Durham, North Carolina, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Is the IVF Outcome Dependent on the Time Interval Between hCG Administration and Oocyte Retrieval?

ClinicalTrials.gov · NCT02044445 · Registry updated: 2014-05-28

Condition / research focus: Subfertility
Sponsor: Aristotle University Of Thessaloniki
Countries with listed sites: Greece
Registry dates and results: Start: 2009-11. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Oocyte retrieval will be performed 36 h or 38 h after hCG administration (procedure) — also listed as: oocyte retrieval at 36 hours following hCG administration, oocyte retrieval at 38 hours following hCG administration

Where the study takes place — 1 listed sites

Unit for Human Reproduction, 1st Dept of Obstetrics and Gynaecology, Medical School, Aristotle University of Thessaloniki
Thessaloniki, Greece
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

GnRH Agonist Triggering Supplemented With Hcg in Women With Poor Ovarian Response

ClinicalTrials.gov · NCT02144818 · Registry updated: 2014-05-22

Condition / research focus: Women With Poor Ovarian Response
Sponsor: Sheba Medical Center
Countries with listed sites: Israel
Registry dates and results: Start: 2014-01. Completion: 2015-07 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ovitrel (drug)
Decapeptyl (drug)

Where the study takes place — 1 listed sites

Sheba medical center
Ramat Gan, Israel
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Feasibility and Acceptability of Using the Semi-quantitative Pregnancy Test in an Assisted Fertility Setting

ClinicalTrials.gov · NCT01846403 · Registry updated: 2014-05-14

Condition / research focus: Embryo Transfer
Sponsor: Gynuity Health Projects
Countries with listed sites: Vietnam
Registry dates and results: Start: 2013-06. Completion: 2013-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semi-quantitative urine pregnancy test (device) — also listed as: (dBest One Step hCG Panel Test Kit)

Where the study takes place — 1 listed sites

Hungvuong Hospital
Ho Chi Minh City, Vietnam
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Corifollitropin Alfa Compared to Daily rFSH in Poor Responders Undergoing ICSI

ClinicalTrials.gov · NCT02046655 · Registry updated: 2014-05-14

Condition / research focus: Subfertility
Sponsor: Aristotle University Of Thessaloniki
Countries with listed sites: Greece
Registry dates and results: Start: 2011-01. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Corifollitropin alfa (drug) — also listed as: Elonva
rFSH (drug) — also listed as: Puregon

Where the study takes place — 1 listed sites

Unit for Human Reproduction, 1st Dept of Obstetrics and Gynaecology, Medical School, Aristotle University of Thessaloniki
Thessaloniki, Greece
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Worldwide Study Finder

Find a study

Registry search results

Evolutive Potential of Embryos Obtained From Oocytes After Luteal Phase Ovarian Stimulation

Explore the world’s study registries

Worldwide

Africa

Americas

Response of VEGF and AT-II to HCG in PCOS

Hormonal Stimulation in IUI Treatment: Is Clomifen Combined With Ethinyl Estradiol Better, Worse or Equal to Menopur

Simplified Medical Abortion in Rural India

Corifollitropin Alfa Application in PCOS Patients

GONAL-f CONSORT (Consistency in r-hFSH Starting Doses for Individualised Treatment)

A Study Using Recombinant Human Chorionic Gonadotrophin (rhCG, Ovidrel®) in the Induction of Final Follicle Maturation and Early Luteinization in Chinese Women Undergoing in Vitro Fertilization and Embryo Transfer (IVF/ET)

Clomiphene Citrate Plus Gonadotropins and GnRH Antagonist Versus Flexible GnRH Antagonist Protocol Versus Microdose GnRH Agonist Protocol in Poor Responders Undergoing IVF

Growth Hormone in Poor Responders to IVF Trial

A Study to Evaluate the Ease of Use, Local Tolerance, Safety and Effectiveness of Gonal-f® (Filled-by-mass in a Prefilled Pen)

A Prospective, Multi-centric Observational Study to Determine the Mono-bifollicular Development in Infertile Women Subjected to Ovulation Induction With Follitropin α

Non-invasive Chromosomal Examination of Trisomy Study

An Observational Study to Compare the Dose of Gonal-fTM FbM Prescribed by the Doctor With the Recommendation of the Dose Calculator Consort and to Evaluate the Ease of Use of Pre-filled Pen of Gonal-fTM FbM Pen

The Role of a Semi-Quantitative Urine Pregnancy Test and Pregnancy Questionnaire After Uterine Evacuation for Undesired Pregnancy of Uncertain Location

Effect of GnRH Antagonist vs Agonist Long on IVF Outcome, Peak Estradiol Level,and Duration of Stimulation

Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath

Is the IVF Outcome Dependent on the Time Interval Between hCG Administration and Oocyte Retrieval?

GnRH Agonist Triggering Supplemented With Hcg in Women With Poor Ovarian Response

Feasibility and Acceptability of Using the Semi-quantitative Pregnancy Test in an Assisted Fertility Setting

Corifollitropin Alfa Compared to Daily rFSH in Poor Responders Undergoing ICSI

Asia

Middle East

Europe

Oceania